An in vitro vaccination protocol led to the generation of CD8 T cultures that exhibited an indistinguishable reactivity to the altered peptide sequence and the natural peptide as well as a highly selective capacity to recognize TAP-deficient tumor cells. The gene discussed is CD8A; the disease is neoplasm.